OmniAb Inc.

1.79
0.02 (1.13%)
At close: Apr 17, 2025, 3:59 PM
1.83
2.23%
After-hours: Apr 17, 2025, 07:54 PM EDT

Company Description

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.

The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.

Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.

The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets.

The company was founded in 2012 and is headquartered in Emeryville, California.

OmniAb Inc.
OmniAb Inc. logo
Country United States
IPO Date Sep 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 114
CEO Matthew W. Foehr

Contact Details

Address:
5980 Horton Street
EmeryVille, California
United States
Website https://www.omniab.com

Stock Details

Ticker Symbol OABI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001846253
CUSIP Number 68218J103
ISIN Number US68218J1034
Employer ID 00-0000000
SIC Code 8731

Key Executives

Name Position
Matthew W. Foehr President, Chief Executive Officer & Director
Charles S. Berkman J.D. Chief Legal Officer & Secretary
Kurt A. Gustafson Executive Vice President of Finance & Chief Financial Officer
Cia McCaffrey Vice President of People & Talent
Donna Ventura CPA Senior Vice President & Corporate Controller
Dr. Bill Harriman Ph.D. Senior Vice President of Antibody Discovery
Dr. Christel Iffland Ph.D. Senior Vice President of Antibody Technologies
Dr. Yasmina Noubia Abdiche Ph.D. Senior Vice President of Exploratory Research
Marie-Cecile van de Lavoir D.V.M., Ph.D. Senior Vice President of Technical Operations & Genetics

Latest SEC Filings

Date Type Title
Apr 07, 2025 4 Filing
Apr 07, 2025 4 Filing
Apr 07, 2025 4 Filing
Apr 01, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 20, 2025 4 Filing
Mar 18, 2025 S-8 Filing
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 19, 2025 4 Filing